Cellectar Biosciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

STOCKHOLDERS' EQUITY (Details)

STOCKHOLDERS' EQUITY (Details)							3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
STOCKHOLDERS' EQUITY (Details)	Sep. 08, 2023 USD ($) $ / shares shares	Oct. 25, 2022 USD ($) $ / shares shares	Oct. 20, 2022 USD ($)	Jun. 27, 2022	Jun. 24, 2022	Dec. 23, 2020 USD ($) $ / shares shares	Mar. 31, 2023 USD ($) $ / shares shares	Jun. 30, 2023 USD ($) $ / shares shares	Sep. 30, 2023 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 $ / shares shares	Oct. 25, 2023 shares	Oct. 24, 2023 shares	Oct. 31, 2022 $ / shares shares	Sep. 30, 2022 $ / shares shares	Jun. 30, 2022 $ / shares shares	Mar. 31, 2022 $ / shares shares
STOCKHOLDERS' EQUITY
Warrants issued to purchase shares										28,002,379
Proceeds from exercise of warrants \| $							$ 3	$ 3	$ 348,641	$ 789,642
Number of warrants exercised										177,877	0
Reverse stock split				0.10
Common stock, shares authorized							170,000,000	170,000,000	170,000,000	170,000,000	170,000,000	170,000,000	160,000,000		160,000,000	160,000,000	160,000,000
Common stock par value \| $ / shares							$ 0.00001	$ 0.00001	$ 0.00001	$ 0.00001	$ 0.00001				$ 0.00001	$ 0.00001	$ 0.00001
September 2023 Private Placement
STOCKHOLDERS' EQUITY
Gross proceeds \| $	$ 24,500,000
Net proceeds \| $	$ 22,200,000
October 2022 Public Offering and Private Placement
STOCKHOLDERS' EQUITY
Warrants issued to purchase shares		3,275,153
Gross proceeds \| $		$ 10,700,000
Proceeds from exercise of warrants \| $										$ 348,638
Exercise price of warrants (in dollars per share) \| $ / shares		$ 2.085
Estimated offering expenses \| $		$ 9,600,000
Other expenses \| $			$ 6,300,000
Common Stock
STOCKHOLDERS' EQUITY
Conversion of pre-funded warrants into common shares (in shares)										9,947,684
Common Stock \| October 2022 Public Offering and Private Placement
STOCKHOLDERS' EQUITY
Warrants issued to purchase shares		1,875,945
Exercise price of warrants (in dollars per share) \| $ / shares		$ 1.96
Minimum \| Common Stock
STOCKHOLDERS' EQUITY
Reverse stock split					0.10
Maximum \| Common Stock
STOCKHOLDERS' EQUITY
Reverse stock split					0.20
Common Stock \| September 2023 Private Placement
STOCKHOLDERS' EQUITY
Convertible preferred shares issued	9,947,684
Common stock par value \| $ / shares	$ 1.82
Series D preferred stock \| Private placement
STOCKHOLDERS' EQUITY
Shares issued						1,000
Preferred shares are convertible into a number of shares of common stock (per shares)						13.50
Price per share \| $ / shares						$ 13,500
Series D Convertible Preferred Stock
STOCKHOLDERS' EQUITY
Shares issued						1,518.5180
Series D Convertible Preferred Stock \| Private placement
STOCKHOLDERS' EQUITY
Preferred shares are convertible into a number of shares of common stock \| $						$ 13,500
Series E Warrants \| September 2023 Private Placement
STOCKHOLDERS' EQUITY
Share price \| $ / shares	$ 20,000
Series E-1 preferred stock \| September 2023 Private Placement
STOCKHOLDERS' EQUITY
Shares issued	1,225
Conversion price per share \| $ / shares	$ 1.82
Convertible preferred shares issued	13,461,538
Gross proceeds from stockholders' equity \| $	$ 17,820,000
Series E-2 Preferred Stock \| September 2023 Private Placement
STOCKHOLDERS' EQUITY
Number of shares converted	905.24
Series E-3 preferred stock \| September 2023 Private Placement
STOCKHOLDERS' EQUITY
Conversion price per share \| $ / shares	$ 3.185
Convertible preferred shares issued	13,846,154
Series E-4 preferred stock \| September 2023 Private Placement
STOCKHOLDERS' EQUITY
Conversion price per share \| $ / shares	$ 4.7775
Convertible preferred shares issued	7,179,487
Tranche A and B Warrants \| September 2023 Private Placement
STOCKHOLDERS' EQUITY
Gross proceeds from stockholders' equity \| $	$ 4,800,000
December 2020 Public Offering \| Private placement
STOCKHOLDERS' EQUITY
Shares issued						1,814,813
Common stock par value \| $ / shares						$ 0.00001
Public offering price of share \| $ / shares						$ 13.50
Common warrants \| October 2022 Public Offering and Private Placement
STOCKHOLDERS' EQUITY
Conversion of pre-funded warrants into common shares (in shares)										355,235
Proceeds from public offering allocated to stock and warrants \| $			6,400,000
Prefunded Warrant \| October 2022 Public Offering and Private Placement
STOCKHOLDERS' EQUITY
Warrants issued to purchase shares		1,875,945
pre-funded warrants										355,235
2023 Tranche A Preferred Warrants \| September 2023 Private Placement
STOCKHOLDERS' EQUITY
Proceeds from exercise of warrants \| $	$ 44,100,000
2023 Tranche A Preferred Warrants \| Series E-3 preferred stock \| September 2023 Private Placement
STOCKHOLDERS' EQUITY
Warrants issued to purchase shares	2,205
Number of days \| $	10
2023 Tranche B Preferred Warrants \| Series E-4 preferred stock \| September 2023 Private Placement
STOCKHOLDERS' EQUITY
Warrants issued to purchase shares	1,715
Proceeds from exercise of warrants \| $	$ 34,300,000
Number of days \| $	10
2022 Pre-Funded Common Warrants
STOCKHOLDERS' EQUITY
Warrants issued to purchase shares														1,875,941
2022 Pre-Funded Common Warrants \| October 2022 Public Offering and Private Placement
STOCKHOLDERS' EQUITY
Exercise price of warrants (in dollars per share) \| $ / shares		$ 0.00001
Purchase price \| $ / shares		$ 2.08499
Proceeds from public offering allocated to stock and warrants \| $			3,700,000
2022 Common Warrants
STOCKHOLDERS' EQUITY
Warrants issued to purchase shares														5,151,098
Exercise price of warrants (in dollars per share) \| $ / shares														$ 1.96
2022 Common Warrants \| October 2022 Public Offering and Private Placement
STOCKHOLDERS' EQUITY
Proceeds from public offering allocated to stock and warrants \| $			$ 7,000,000.0